David A. Siegel Iveric Bio, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$26.24 - $39.63 $3.55 Million - $5.36 Million	135,300 New	135,300 $5.32 Million
Q4 2022 Feb 14, 2023	SELL	$17.24 - $23.95 $9 Million - $12.5 Million	-522,000 Reduced 86.86%	79,000 $1.69 Million
Q3 2022 Nov 14, 2022	SELL	$9.4 - $18.59 $9.66 Million - $19.1 Million	-1,027,900 Reduced 63.1%	601,000 $10.8 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $3.23 Million - $6.68 Million	353,700 Added 27.74%	1,628,900 $15.7 Million
Q1 2022 May 16, 2022	SELL	$12.15 - $16.83 $255,150 - $353,429	-21,000 Reduced 1.62%	1,275,200 $21.5 Million
Q4 2021 Feb 14, 2022	BUY	$13.83 - $18.78 $6.08 Million - $8.25 Million	439,500 Added 51.3%	1,296,200 $21.7 Million
Q3 2021 Nov 15, 2021	BUY	$7.07 - $17.5 $3.51 Million - $8.7 Million	497,100 Added 138.24%	856,700 $13.9 Million
Q2 2021 Aug 16, 2021	BUY	$5.69 - $7.17 $657,764 - $828,852	115,600 Added 47.38%	359,600 $2.27 Million
Q1 2021 May 17, 2021	BUY	$5.08 - $6.89 $277,876 - $376,883	54,700 Added 28.9%	244,000 $1.51 Million
Q4 2020 Feb 16, 2021	BUY	$5.65 - $7.66 $392,675 - $532,370	69,500 Added 58.01%	189,300 $1.31 Million
Q3 2020 Nov 16, 2020	SELL	$4.01 - $6.29 $52,932 - $83,028	-13,200 Reduced 9.92%	119,800 $676,000
Q2 2020 Aug 14, 2020	BUY	$3.06 - $6.6 $177,480 - $382,800	58,000 Added 77.33%	133,000 $678,000
Q1 2020 May 15, 2020	BUY	$2.83 - $8.44 $134,708 - $401,744	47,600 Added 173.72%	75,000 $258,000
Q4 2019 Feb 14, 2020	SELL	$0.93 - $8.58 $17,391 - $160,446	-18,700 Reduced 40.56%	27,400 $235,000
Q3 2019 Nov 14, 2019	SELL	$1.09 - $1.29 $11,554 - $13,674	-10,600 Reduced 18.69%	46,100 $52,000
Q2 2019 Aug 14, 2019	BUY	$1.21 - $1.48 $68,607 - $83,916	56,700 New	56,700 $74,000

Others Institutions Holding ISEE

# of Institutions

Shares Held

250K

Call Options Held

40K

Put Options Held

View Full List

About IVERIC bio, Inc.

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

More about ISEE

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account